Physicians at University of Utah Health report that molecular imaging may reduce the number of biopsies needed to evaluate suspected melanoma, a shift that could reshape how dermatologists triage pigmented lesions in high-risk clinics.

The announcement centers on a concept dermatology has pursued for years: a noninvasive imaging method capable of resolving the molecular signature of a lesion before any tissue is removed. If validated in broader clinical use, the approach would address one of the most persistent problems in skin-cancer detection — the large share of biopsies performed on lesions that ultimately prove benign.

The stakes are concrete. Patients with atypical mole syndromes, a personal history of melanoma, or extensive dysplastic nevi routinely undergo serial excisions and punch biopsies. Each procedure carries costs: scarring, patient anxiety, infection risk, and cumulative health-system expense. Any technology that improves the positive predictive value of the decision to biopsy would change practice economics as much as clinical workflow.

Molecular imaging differs from established noninvasive tools such as dermoscopy and reflectance confocal microscopy in a specific way. Rather than relying on morphological features — asymmetry, network atypia, vascular patterns — it targets molecular markers associated with malignant transformation. That distinction matters for lesions that look ambiguous under the dermatoscope, where morphology alone cannot reliably separate a benign nevus from an early melanoma.

The University of Utah Health report frames the technology as a potential filter upstream of the biopsy decision. In that model, a clinician would image a suspicious lesion, obtain a molecular readout, and reserve tissue sampling for lesions whose imaging signature indicates genuine risk. The report does not claim the technology eliminates biopsies; it positions molecular imaging as a way to reduce their number.

For dermatologists, the clinical logic is familiar. melanoma surveillance depends on early detection, and the current standard accepts substantial over-biopsy as the price of sensitivity. Any instrument that maintains sensitivity while improving specificity would let clinicians reserve excisions for lesions that warrant them. In pigmented-lesion clinics, where a single patient may generate dozens of biopsy decisions per year, even a modest improvement in diagnostic precision compounds quickly.

The report arrives amid broader momentum in noninvasive skin-cancer diagnostics, where optical and molecular technologies are competing to become the first widely adopted adjunct to dermoscopy. University of Utah Health's involvement reflects the institution's long-standing melanoma program and its access to high-risk cohorts — the patient populations in whom a biopsy-sparing tool would have the greatest measurable effect.

Key questions will determine whether the technology moves from report to routine. Clinicians will want sensitivity and specificity figures against histopathology as the reference standard, performance in amelanotic and nodular melanomas, and data on how the imaging step affects time to diagnosis. Reimbursement pathways and device availability will shape adoption just as much as diagnostic performance.

For now, the University of Utah Health report signals a direction rather than a finished protocol: molecular imaging as a means of reducing unnecessary melanoma biopsies while preserving the early-detection standard that drives melanoma survival. Prospective validation in high-risk cohorts will determine whether it earns a place alongside dermoscopy in the pigmented-lesion clinic.